Document is current
Any future updates will be listed below
-
Authors
Mattheisen, Manuel http://orcid.org/0000-0002-8442-493X
Grove, Jakob http://orcid.org/0000-0003-2284-5744
Als, Thomas D. http://orcid.org/0000-0002-2963-1928
Martin, Joanna
Voloudakis, Georgios http://orcid.org/0000-0002-5729-632X
Meier, Sandra
Demontis, Ditte http://orcid.org/0000-0001-9124-2766
Bendl, Jaroslav http://orcid.org/0000-0001-9989-2720
Walters, Raymond http://orcid.org/0000-0001-8422-6530
Carey, Caitlin E.
Rosengren, Anders http://orcid.org/0000-0002-6682-1288
Strom, Nora I. http://orcid.org/0000-0002-5261-8852
Hauberg, Mads Engel http://orcid.org/0000-0003-4873-2764
Zeng, Biao
Hoffman, Gabriel http://orcid.org/0000-0002-0957-0224
Zhang, Wen
Bybjerg-Grauholm, Jonas http://orcid.org/0000-0003-1705-4008
Bækvad-Hansen, Marie
Agerbo, Esben http://orcid.org/0000-0002-2849-524X
Cormand, Bru http://orcid.org/0000-0001-5318-4382
Nordentoft, Merete
Werge, Thomas http://orcid.org/0000-0003-1829-0766
Mors, Ole
Hougaard, David M. http://orcid.org/0000-0001-5928-3517
Buxbaum, Joseph D. http://orcid.org/0000-0001-8898-8313
Faraone, Stephen V.
Franke, Barbara http://orcid.org/0000-0003-4375-6572
Dalsgaard, Søren http://orcid.org/0000-0003-4659-0969
Mortensen, Preben B.
Robinson, Elise B.
Roussos, Panos http://orcid.org/0000-0002-4640-6239
Neale, Benjamin M. http://orcid.org/0000-0003-1513-6077
Daly, Mark J.
Børglum, Anders D. http://orcid.org/0000-0001-8627-7219
- License Information
-
More Information
Article History
Received: 1 June 2021
Accepted: 20 June 2022
First Online: 26 September 2022
Competing interests
: B.F. has received educational speaking fees from Medice. In the past year, S.V.F. has received income, potential income, travel expenses, continuing education support and/or research support from Takeda, OnDosis, Tris, Otsuka, Arbor, Ironshore, Rhodes, Akili Interactive Labs, Sunovion, Supernus and Genomind. With his institution, S.V.F. has US patent US20130217707 A1 for the use of sodium–hydrogen exchange inhibitors in the treatment of ADHD. S.V.F. also receives royalties from books published by Guilford Press (<i>Straight Talk about Your Child’s Mental Health</i>), Oxford University Press (<i>Schizophrenia: The Facts</i>) and Elsevier (<i>ADHD: Non-Pharmacologic Interventions</i>). S.V.F. is Program Director of . B.M.N. is a member of the scientific advisory board at Deep Genomics and Neumora (formerly Neumora) and consultant for Camp4 Therapeutics, Takeda Pharmaceutical and Biogen. M.J.D. is a founder of Maze Therapeutics and is on the Scientific Advisory Board of RBNC Therapeutics. The other authors declare no competing interests.
